QuidelOrtho (QDEL) Projected to Post Quarterly Earnings on Wednesday

QuidelOrtho (NASDAQ:QDEL) is projected to release its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect QuidelOrtho to post earnings of $0.54 per share and revenue of $699.7950 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.29. The company had revenue of $699.90 million for the quarter, compared to the consensus estimate of $667.45 million. QuidelOrtho had a positive return on equity of 5.75% and a negative net margin of 42.53%.The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period last year, the firm earned $0.85 EPS. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

QuidelOrtho Stock Performance

NASDAQ QDEL opened at $27.98 on Wednesday. The firm has a market capitalization of $1.90 billion, a P/E ratio of -1.64 and a beta of 0.68. The stock has a 50-day simple moving average of $29.49 and a two-hundred day simple moving average of $27.65. The company has a debt-to-equity ratio of 1.23, a quick ratio of 0.98 and a current ratio of 1.78. QuidelOrtho has a fifty-two week low of $19.50 and a fifty-two week high of $44.68.

Insider Activity

In related news, CEO Brian J. Blaser purchased 23,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The shares were purchased at an average cost of $21.34 per share, with a total value of $501,490.00. Following the purchase, the chief executive officer owned 29,533 shares of the company’s stock, valued at $630,234.22. This represents a 389.52% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joseph M. Busky acquired 4,770 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was purchased at an average price of $26.06 per share, for a total transaction of $124,306.20. Following the completion of the acquisition, the chief financial officer owned 6,920 shares in the company, valued at $180,335.20. The trade was a 221.86% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 29,390 shares of company stock valued at $657,340. Insiders own 0.79% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QDEL. CIBC Bancorp USA Inc. acquired a new stake in QuidelOrtho during the 3rd quarter worth $213,000. Verition Fund Management LLC lifted its stake in shares of QuidelOrtho by 52.6% in the third quarter. Verition Fund Management LLC now owns 69,736 shares of the company’s stock worth $2,054,000 after buying an additional 24,031 shares in the last quarter. Newtyn Management LLC boosted its position in QuidelOrtho by 58.3% during the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after acquiring an additional 994,332 shares during the last quarter. Millennium Management LLC purchased a new stake in QuidelOrtho during the 3rd quarter valued at about $10,932,000. Finally, Larson Financial Group LLC grew its stake in QuidelOrtho by 322.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

Analyst Ratings Changes

QDEL has been the subject of several recent research reports. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 13th. UBS Group lifted their target price on shares of QuidelOrtho from $31.00 to $35.00 and gave the company a “neutral” rating in a report on Wednesday, January 21st. Citigroup reiterated a “neutral” rating and issued a $33.00 target price (down from $40.00) on shares of QuidelOrtho in a research note on Tuesday, October 7th. JPMorgan Chase & Co. dropped their price target on shares of QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $39.00.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.